Study of the Fosfosal Controlled Permeation through Glutaraldehyde Crosslinked Chitosan Membranes

Abstract:

Article Preview

Fosfosal, a phosphate derivative of salicylic acid, which presents both analgesic and antiinflammatory properties, was used as a model drug to study the potential of recently developed chitosan membranes (with different crosslinking degrees) to be used as drug release rate-controlling membranes. The fosfosal permeation across these membranes was studied using an in-house built developed diffusion cell with online automatic monitoring. Experiments were performed using phosphate buffer saline (PBS) solution at 37°C. Different flow properties of the detection set up were determined in order to estimate the errors introduced by the automatic online monitoring system. For increasing crosslinking degrees the permeability initially decreased, and then increased, likely as a consequence of the crosslinking influence on a variety of properties like crystallinity and hydrophilicity that have opposite influence on permeability. In summary, it was possible to control the drug release profile by means of changing the degree of crosslinking of chitosan membranes and to follow the respective release kinetics by means of using the developed diffusion cell.

Info:

Periodical:

Materials Science Forum (Volumes 514-516)

Edited by:

Paula Maria Vilarinho

Pages:

990-994

DOI:

10.4028/www.scientific.net/MSF.514-516.990

Citation:

R. M.P. da Silva et al., "Study of the Fosfosal Controlled Permeation through Glutaraldehyde Crosslinked Chitosan Membranes", Materials Science Forum, Vols. 514-516, pp. 990-994, 2006

Online since:

May 2006

Export:

Price:

$35.00

[1] Monteiro OAC, Airoldi C, Int J Biol Macromol 26 (2-3) (1999), 119-28.

[2] Silva RM, Silva GA, et al, J Mater Sci-Mater Med 15 (2004), 1105-12.

[3] Park YJ, Lee YM, et al, J Control Release 67 (2-3) (2000), 385-94.

[4] Silva RM, Malafaya PB, et al, in Bioceramics 15 (2003), 423-26.

[5] Ma L, Gao CY, et al, Biomaterials 24 (26) (2003), 4833-41.

[6] Ma JB, Wang HJ, et al, Biomaterials 22 (4) (2001), 331-36.

[7] Khoo CGL, Frantzich S, et al, Eur J Pharm Biopharm 55 (1) (2003), 47-56.

[8] Thacharodi D and Rao KP, Biomaterials 17 (13) (1996), 1307-11.

[9] Thacharodi D and Rao KP, Biomaterials 16(2) (1995), 145-48.

[10] Bosman IJ, Avegaart SR, et al, J Pharmaceut Biomed (1998) 17(3), 493-99.

[11] Kierstan KTE, Beezer AE, et al, Int J Pharm 229 (1-2) (2001), 87-94.

[12] Martin B, Watts O, et al, Int J Pharm 49(1) (1989), 63-68.

[13] Rinaudo M, Pavlov G, et al, Polymer 40(25) (1999), 7029-32.

In order to see related information, you need to Login.